Lonza to acquire Synaffix to strengthen ADC development

Published on June 16, 2023

Synaffix’s technology platform is intended to enhance and extend Lonza’s integrated ADC services

Continue reading on website
Other news

Lonza strengthens ADC offering with Synaffix acquisition

June 16, 2023
Lonza has acquired Synaffix B.V., a biotech company focused on commercializing its clinical-stage technology platform for the development of antibody drug conjugates (ADCs).

Rentschler Biopharma and Ikarovec partner to expedite new gene therapies

June 16, 2023
Rentschler Biopharma has collaborated with Ikarovec for expediting the new gene therapies to treat ophthalmic disease.Under the deal, Rentschler Biopharma’s ATMP facility in Stevenage, UK, will undertake the bioprocess development of adeno-associated virus (AAV) material.The AAV material will be used for the planned pre-clinical testing of the new gene therapy of Ikarovec to treat geographic atrop